TRIALS

Community-acquired pneumonia (CAP) is considered the leading cause of death from infectious disease in de-veloped countries. Increased mortality is associated with systemic manifestations and complications of CAP, with sepsis being the most common and challenging. The incidence of sepsis increases with age, while age is also a predictor of outcome in patients with pneumonia [1]. Sepsis is characterised by a state of systemic immune dysregulation and coagulopathy produced by invasive microorganisms and/or their microbial products, such as lipopolysaccharide (LPS). The initial cytokine storm and systemic inflammatory response syndrome (SIRS) i